Clinical trial NCT00361309: SU011248 in Advanced Hepatocellular Carcinoma
Official title: A Phase II Study of SU011248 in Advanced Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hepatocellular Carcinoma
Liver Cancer
Keywords: liver cancer
HCC
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Beth Israel Deaconess Medical Center
name: Brigham and Women's Hospital
name: Dana-Farber Cancer Institute
First posted: 2006-08-08
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to begin to collect information and try to learn whether SU011248 works in treating patients with advanced liver cancer. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further.

Detailed description: * Participants will be given a supply of SU011248 capsules to be taken orally every morning for 4 weeks. After taking SU011248 for 4 weeks, there will be a 2 week rest period when the participant will not take any capsules. This 6-week period is referred to as 1 cycle.
* Participants will continue to receive SU011248 study treatment as long as their disease does not worsen significantly and they are not experiencing any serious side effects.
* During cycle 1 of study treatment, the participant will come to the outpatient clinic once a week for blood work, physical examination and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), which is done two weeks after they start taking study treatment.
* During cycle two and every cycle thereafter, the participant will be asked to come to the outpatient clinic once every two weeks for physical examination, blood work and urine tests.
* A CT scan or MRI scan to assess the tumor will be performed once during each cycle for the first three cycles, then once every 2 cycles thereafter. ACTH stimulation test will be done every 2 cycles. A MUGA scan may be done at anytime at the discretion of the the study doctor.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed HCC and should have metastatic or locally advanced unresectable disease
* Measurable disease
* 0-1 prior systemic chemotherapy regimens for HCC
* Age 18 years or older
* Life expectancy of greater than 12 weeks
* ECOG performance status of 0-1
* Adequate organ and marrow function
* Women of child-bearing potential must have a negative pregnancy test prior to study entry

Exclusion Criteria:

* Chemotherapy, radiotherapy or major surgery within 4 weeks of study entry
* Receiving any other investigational agents within past 30 days
* Known brain metastases
* CLIP score \> 3
* Chronic diarrhea or any disorder that will limit adequate absorption of SU011248
* Prolongation of QTc \> 450 msec in screening electrocardiogram or history of familial long QT syndrome
* Uncontrolled intercurrent illness
* Pregnant or lactating women
* Greater than or equal to 2g of protein/24hr

Primary outcomes:
measure: Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.
timeFrame: 2 years
Secondary outcomes:
measure: Number of adverse events in patients treated with SU011248 for advanced hepatocellular carcinoma
timeFrame: 2 years
measure: Objective Response Rate
timeFrame: 2 years
measure: Overall Survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Andrew X. Zhu, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol. 2013 Jul 10;6:51. doi: 10.1186/1756-8722-6-51.